Covid-19 vaccine in India. The Subject Expert Committee evaluated the submitted protocol by SII and asked the Pune-based firm to revise its protocol for the phase 2 and 3 clinical trials, besides seeking some additional information.On Wednesday evening, SII submitted a revised protocol for conducting the trials to the DCGI.
Additional Director, Government Affairs, SII, Prakash Kumar Singh said, "We have submitted our revised protocol to DCGI office today evening for further action by SEC and DCGI.""The company on Tuesday was asked to clearly define phase 2 and phase 3 part of the protocol and resubmit their application for evaluation by the SEC," an official source said.